Lakewood-Amedex Biotherapeutics Nasdaq/NYSE Compliance Notice
Lakewood-Amedex Biotherapeutics received a delisting notice from Nasdaq on November 10, 2026, because its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days. Due to a prior reverse stock split within the last year, the company is ineligible for a standard compliance period and faces immediate suspension unless it successfully appeals to a Nasdaq Hearings Panel. The company intends to request a hearing to stay the delisting and present a plan to regain compliance.
- Counterparty
- The Nasdaq Stock Market LLC